Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cumberland Pharmaceuticals Inc. CPIX

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology and oncology. The company promotes its approved products through its hospital, field and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived primarily from the product sales of FDA approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ..


Recent & Breaking News (NDAQ:CPIX)

Cumberland Pharmaceuticals Reports 14% Revenue Growth

PR Newswire August 9, 2022

CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021

PR Newswire August 8, 2022

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS

PR Newswire August 2, 2022

CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS

PR Newswire July 19, 2022

Cumberland Pharmaceuticals Reports 6% Revenue Growth

PR Newswire May 10, 2022

Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®

PR Newswire May 9, 2022

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS

PR Newswire May 3, 2022

TABUK AND CUMBERLAND PARTNER TO BRING INNOVATIVE ANTIBIOTIC WITH LIFE-SAVING POTENTIAL TO MIDDLE EAST

PR Newswire March 31, 2022

CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS & COMPANY UPDATE

PR Newswire March 8, 2022

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2021 FINANCIAL RESULTS

PR Newswire March 1, 2022

CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO® FROM KYOWA KIRIN NORTH AMERICA

PR Newswire January 4, 2022

Caldolor® Now FDA Approved For Pre-Operative Administration

PR Newswire November 29, 2021

Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update

PR Newswire November 9, 2021

Cumberland Pharmaceuticals To Announce Third Quarter 2021 Financial Results

PR Newswire November 2, 2021

Cumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis

PR Newswire September 29, 2021

Cumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update

PR Newswire August 10, 2021

Cumberland Pharmaceuticals To Announce Second Quarter 2021 Financial Results

PR Newswire August 3, 2021

Cumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020

PR Newswire July 26, 2021

Vibativ® Effectively Helps Treat Secondary Bacterial Infections In COVID-19 Patients

PR Newswire June 21, 2021

Cumberland Pharmaceuticals Names John Hamm New Chief Financial Officer

PR Newswire May 19, 2021